[go: up one dir, main page]

WO2006128455A3 - Compounds modifying apoptosis - Google Patents

Compounds modifying apoptosis Download PDF

Info

Publication number
WO2006128455A3
WO2006128455A3 PCT/DK2006/000280 DK2006000280W WO2006128455A3 WO 2006128455 A3 WO2006128455 A3 WO 2006128455A3 DK 2006000280 W DK2006000280 W DK 2006000280W WO 2006128455 A3 WO2006128455 A3 WO 2006128455A3
Authority
WO
WIPO (PCT)
Prior art keywords
apoptosis
compounds
compounds modifying
modifying apoptosis
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2006/000280
Other languages
French (fr)
Other versions
WO2006128455A2 (en
Inventor
Ole Thastrup
Jens Norrild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2005/000347 external-priority patent/WO2005116656A1/en
Application filed by Individual filed Critical Individual
Priority to US11/914,994 priority Critical patent/US8318717B2/en
Priority to AU2006254538A priority patent/AU2006254538A1/en
Priority to EP06742429.1A priority patent/EP1888619B1/en
Publication of WO2006128455A2 publication Critical patent/WO2006128455A2/en
Publication of WO2006128455A3 publication Critical patent/WO2006128455A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to compounds capable of inhibiting binding of the Smac protein to Inhibitors of apoptosis (IAPs). Such compounds are preferably capable of inhibiting IAP and thus may promote apoptosis or sensitize cells for apoptosis. The compounds may be used in the treatment of proliferative diseases, such as cancer.
PCT/DK2006/000280 2005-05-25 2006-05-23 Compounds modifying apoptosis Ceased WO2006128455A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/914,994 US8318717B2 (en) 2005-05-25 2006-05-23 Compounds modifying apoptosis
AU2006254538A AU2006254538A1 (en) 2005-05-25 2006-05-23 Compounds modifying apoptosis
EP06742429.1A EP1888619B1 (en) 2005-05-25 2006-05-23 Compounds modifying apoptosis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/DK2005/000347 WO2005116656A1 (en) 2004-05-25 2005-05-25 Identification of compounds modifying a cellular response
DKPA200500763 2005-05-25
DKPCT/DK2005/000347 2005-05-25
DKPA200500763 2005-05-25
DKPA200501663 2005-11-25
DKPA200501663 2005-11-25

Publications (2)

Publication Number Publication Date
WO2006128455A2 WO2006128455A2 (en) 2006-12-07
WO2006128455A3 true WO2006128455A3 (en) 2007-04-12

Family

ID=37482012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2006/000280 Ceased WO2006128455A2 (en) 2005-05-25 2006-05-23 Compounds modifying apoptosis

Country Status (3)

Country Link
EP (1) EP1888619B1 (en)
AU (1) AU2006254538A1 (en)
WO (1) WO2006128455A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5230865B2 (en) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション IAP binding compound
DK1851200T3 (en) 2005-02-25 2014-04-14 Tetralogic Pharm Corp DIMER IAP INHIBITORS
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI543988B (en) 2006-03-16 2016-08-01 科學製藥股份有限公司 Iap bir domain binding compounds
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
EP2049563B1 (en) 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
JP5452223B2 (en) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション IAP inhibitor
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
GB2472563B (en) * 2009-04-28 2013-02-27 Univ Leicester Method of preparing hairpin and cyclic polyamides
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
MX2013007677A (en) 2010-12-30 2013-07-30 Abbvie Inc Macrocyclic hepatitis c serine protease inhibitors.
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
KR20140011773A (en) * 2012-07-19 2014-01-29 한미약품 주식회사 Heterocyclic derivatives with dual inhibitory activity
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695757A2 (en) * 1994-08-01 1996-02-07 Arizona Board Of Regents Human cancer inhibitory peptide amides
WO2002096930A2 (en) * 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO2004072105A2 (en) * 2003-02-12 2004-08-26 The Trustees Of Princeton University Iap-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
WO2005116656A1 (en) * 2004-05-25 2005-12-08 2Curex Identification of compounds modifying a cellular response

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695757A2 (en) * 1994-08-01 1996-02-07 Arizona Board Of Regents Human cancer inhibitory peptide amides
WO2002096930A2 (en) * 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO2004072105A2 (en) * 2003-02-12 2004-08-26 The Trustees Of Princeton University Iap-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
WO2005116656A1 (en) * 2004-05-25 2005-12-08 2Curex Identification of compounds modifying a cellular response

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRIAN MCRAE ET AL.: "Studies on Reactivity of Human Leukocyte Elastase, Cathepsin G, and Procine Pancreatic Elastase toward Peptides Including Sequences Related to the Reactive Site of alpha1-Protease Inhibitor (alpha1-Antitrypsin)", BIOCHEMISTRY, vol. 19, 1980, pages 3973 - 3978, XP002415587 *
GROTH T ET AL: "PEG BASED RESINS FOR PROTEASE DRUG DISCOVERY SYNTHESIS, SCREENING AND ANALYSIS OF COMBINATORIAL ON-BEAD LIBRARIES", COMBINATORIAL CHEMISTRY AND HIGH THROUGHPUT SCREENING, HILVERSUM, NL, vol. 6, no. 7, November 2003 (2003-11-01), pages 589 - 610, XP008033922, ISSN: 1386-2073 *
KIPP R A ET AL: "Molecular targeting of inhibitor of apoptosis based on small molecule mimics of natural binding partners", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 41, no. 23, 2002, pages 7344 - 7349, XP002962287, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
EP1888619B1 (en) 2013-04-17
EP1888619A2 (en) 2008-02-20
WO2006128455A2 (en) 2006-12-07
AU2006254538A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2006128455A3 (en) Compounds modifying apoptosis
WO2007081974A3 (en) Viral hepatitis treatment
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2009064486A3 (en) Inhibitors of pim protein kinases, compositions, and methods for treating cancer
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007149482A3 (en) Xanthohumol based protein kinase modulation cancer treatment
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2007075525A3 (en) Combination of an iap-inhibitor and a taxane7
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
WO2006020060A3 (en) Iap binding compounds
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
WO2008076278A8 (en) Methods of cancer treatment with igf1r inhibitors
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
PL2231636T3 (en) Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
WO2006104945A3 (en) Hepatitis c therapies
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2006072615A3 (en) Triazolophthalazines as pde2-inhibitors
WO2008061108A3 (en) Phthalazine derivatives
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2008021250A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
EA200901249A1 (en) PROTEINKINAZ BINDING INHIBITORS
WO2006119510A3 (en) Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006254538

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006742429

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006254538

Country of ref document: AU

Date of ref document: 20060523

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006254538

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006742429

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11914994

Country of ref document: US